

Special Issue

Current Development of Vaccines for Respiratory Viral Infection

Message from the Guest Editor

Viral respiratory tract infections constitute a substantial disease burden in the population, particularly among young children and older adults. More than 25 viruses have been linked to respiratory infections, including common respiratory pathogens such as rhinovirus (RV), respiratory syncytial virus (RSV), influenza virus (Flu), human metapneumovirus (hMPV), parainfluenza viruses (PIV) and human coronaviruses (CoVs). This Special Issue of *Vaccines* focuses on the most recent progress and current vaccine development trends in the field of respiratory viral infection. We invite you to contribute with an original research article, review or perspective on the latest research to highlight novel experimental vaccine candidates, scientific data on supporting vaccine strategies, immune responses elicited by a novel vaccine and concerns and optimisations relating vaccine strategies. This Special Issue emphasises major infectious diseases caused by respiratory viruses, but related topics on co-infections are also welcomed. We look forward to receiving your contributions.

Guest Editor

Dr. Ting Shi
Edinburgh Medical School, Edinburgh, UK

Deadline for manuscript submissions

closed (30 April 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/178731

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).